Furness comes to CHPA from the Food and Drug Administration where he spent more than 25 years in various leadership roles.

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

Trump's order seeks to ease regulations to compel more U.S. drug manufacturing. He also plans to assess tariffs on drug ...

Advanced Preparation for New Drug Application ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical ...

The following year, legislators in the Golden State approved another measure that, starting in 2028, will ban six food dyes — Blue 1, Blue 2, Green 3, Red 40, Yellow 5 and Yellow 6 — from being sold ...

House Republican leaders are trying to resolve sharp differences over the giant budget reconciliation bill after it stalled ...

In the US, for example, the FDA now provides the opportunity for ... A strategic partner Regulatory affairs as a function has undergone a significant shift in its strategic role and impact over ...

While the global drug supply chain has allowed drug companies to make cheaper drugs with fewer regulatory barriers ... CivicaRx's chief government affairs and public policy officer.

Two senior officials at the FDA's drug promotion regulatory office have resigned, leading to speculation that a clampdown on some direct-to-consumer (DTC) advertising of medicines could be on the way.

Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approval "In the first quarter of 2025, we achieved a major milestone for Aquestive with the submission ...